Compare BELFB & VIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BELFB | VIR |
|---|---|---|
| Founded | 1949 | 2016 |
| Country | United States | United States |
| Employees | 4964 | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.5B | 1.5B |
| IPO Year | N/A | 2019 |
| Metric | BELFB | VIR |
|---|---|---|
| Price | $209.79 | $9.47 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 8 |
| Target Price | ★ $174.25 | $19.63 |
| AVG Volume (30 Days) | 135.8K | ★ 4.3M |
| Earning Date | 01-01-0001 | 05-25-2026 |
| Dividend Yield | ★ 0.14% | N/A |
| EPS Growth | N/A | ★ 17.49 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $68,556,000.00 |
| Revenue This Year | $28.52 | N/A |
| Revenue Next Year | $7.85 | $925.73 |
| P/E Ratio | $42.80 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $58.00 | $4.16 |
| 52 Week High | $248.61 | $10.91 |
| Indicator | BELFB | VIR |
|---|---|---|
| Relative Strength Index (RSI) | 49.59 | 57.65 |
| Support Level | $130.49 | $4.64 |
| Resistance Level | $248.61 | $10.91 |
| Average True Range (ATR) | 9.24 | 0.61 |
| MACD | -1.85 | -0.05 |
| Stochastic Oscillator | 45.77 | 49.69 |
Bel Fuse Inc designs and manufactures electronic components that protect and connect electronic circuits. Its product portfolio is divided into three categories: magnetic solutions, power solutions & protection, and connectivity solutions. These products are used for the computer, networking, telecommunications, transportation and defense/aerospace, automotive, medical, and consumer electronics industries. Its geographical segments are the United States, Macao, United Kingdom, Slovakia, Germany, Switzerland, and All other foreign countries. Majority of the revenue is derived from United States.
Vir Biotechnology Inc is a clinical-stage biopharmaceutical company focused on powering the immune system by discovering and developing medicines for serious infectious diseases and cancer. The company uses its capabilities in antibody discovery and engineering, coupled with its proprietary AI engine dAIsY system, and the PRO-XTEN masking platform, to quickly and effectively discover and optimize potential new medicines. Its clinical development pipeline consists of investigational therapies like Tobevibart + elebsiran targeting the hepatitis delta virus (HDV), preclinical antibody candidates targeting HIV, and VIR-5500, VIR-5818, VIR-5525, and 7 PRO-XTEN programs targeting multiple solid tumors. Currently, the company generates revenue mainly by issuing license rights and through grants.